OncoMed Pharmaceuticals (OncoMed Pharmaceuticals) Additional Paid-In Capital : $410.01 Mil(As of Dec. 2018)

View and export this data going back to 2013. Start your Free Trial

What is OncoMed Pharmaceuticals Additional Paid-In Capital?

OncoMed Pharmaceuticals's quarterly additional paid-in capital increased from Jun. 2018 ($407.23 Mil) to Sep. 2018 ($408.87 Mil) and increased from Sep. 2018 ($408.87 Mil) to Dec. 2018 ($410.01 Mil).

OncoMed Pharmaceuticals's annual additional paid-in capital increased from Dec. 2016 ($389.62 Mil) to Dec. 2017 ($403.08 Mil) and increased from Dec. 2017 ($403.08 Mil) to Dec. 2018 ($410.01 Mil).

OncoMed Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for OncoMed Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoMed Pharmaceuticals Additional Paid-In Capital Chart

OncoMed Pharmaceuticals Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Additional Paid-In Capital

Get a 7-Day Free Trial

300.79

313.34

389.62

403.08

410.01

OncoMed Pharmaceuticals Quarterly Data
	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18
Additional Paid-In Capital	Get a 7-Day Free Trial															403.08	405.40	407.23	408.87	410.01

OncoMed Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

OncoMed Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of OncoMed Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoMed Pharmaceuticals (OncoMed Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoMed Pharmaceuticals Inc (NAS:OMED) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

800 Chesapeake Drive, Redwood City, CA, USA, 94063

Website

http://www.oncomed.com

OncoMed Pharmaceuticals Inc is a clinical-stage biotechnology company. The aim of the company is to address cancer initiation, growth, metastases, and recurrence by developing alternative therapies to fight cancer. Its core therapy uses monoclonal antibodies targeting cancer stem cells. The company has strategic alliances with Celgene, Bayer Pharma, and GlaxoSmithKline.

Executives

Perry A Karsen	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Deepika Pakianathan	director	160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Jack W Lasersohn	director	18 BANK STREET, SUMMIT NJ 07901
Jonathan D Root	director	2735 SAND HILL ROAD, MENLO PARK CA 94025
Michael S Wyzga	director	RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02139
Rick E Winningham	director	901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Denise Scots-knight	director	C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Sunil Patel	officer: See Remarks	11085 NORTH TORREY PINES RD., SUITE 300, LA JOLLA CA 92037
Paul J Hastings	officer: Chairman & CEO	61 HARTFORD STREET, SAN FRANCISCO CA 94114
Laurence Lasky	director	C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Jakob Dupont	officer: SVP & Chief Medical Officer	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Terry P Gould	director	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Usvp Entrepreneur Partners Viii A L P	10 percent owner	P O BOX 7460, MENLO PARK CA 94026
Usvp Entrepreneur Partners Viii B L P	10 percent owner	P O BOX 7460, MENLO PARK CA 94026
Usvp Viii Affiliates Fund L P	10 percent owner	2735 SAND HILL ROAD, MENLO PARK CA 94025